A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG

JBI-802

LSD1/HDAC6 Inhibitor

DRUG

Pembrolizumab

PD-1

Trial Locations (1)

RECRUITING

The Christ Hospital, Cincinnati

All Listed Sponsors

lead

The Christ Hospital

OTHER